In patients with Parkinson disease psychosis, treatment with pimavanserin has a lower risk for mortality compared with quetiapine or combination therapy.
In patients with Parkinson disease psychosis, treatment with pimavanserin has a lower risk for mortality compared with quetiapine or combination therapy.